Механизмы агрегации мутантных белков в моделях болезни Хантингтона и амиотрофического бокового склероза
Диссертация
Хантингтин не имеет гомологии с другими известными белками, а его молекулярная масса составляет 350 кДа. В N-концевой части белка расположен полиглутаминовый домен, за которым следует домен, богатый пролином, и три HEAT домена, названные так по четырем белкам, в которых они впервые были обнаружены: хантингтин, фактор элонгации 3, регуляторная субъединица А, фосфатазы А2 и TORI (Рис. 1… Читать ещё >
Список литературы
- Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. // Trends in Cell Biology. 2000, 10: 524−530.
- Muchowski P.J., Wacker J.L. Modulation of neurodegeneration by molecular chaperones. // Nature reviews. 2005. 6: 11−22.
- Hebb M.O. Huntington’s disease: bridging clinical and basic neurobiology//UTMJ. 1999. 76(2): 80−85.
- Bossy-Wetzel E., Schwarzenbacher R., Lipton S.A. Molecular pathways to neurodegeneration // Nature Medicine. 2004. 10: 52−59.
- Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions // Cell. 1998. 95: 55−66.
- Dedeoglu A., Kubilus J.K., Jeitner T.M., Matson S.A., Bogdanov M., Kowall N.W., Matson W.R., Cooper A.J., Ratan R.R., Beal M.F., Hersch S.M.,
- Ferrante R.J. Therapeutic effects of cystamine in a murine model of Huntington’s disease // J Neurosci. 2002. 22(20): 8942−8950.
- Kahlem P., Green H., Djian P. Transglutaminase action imitates Huntington’s disease: selective polymerization of huntingtin containing expanded polyglutamine//Molecular Cell. 1998. 1: 595−601.
- Hoffner G., Djian P. Protein aggregation’in Huntington’s disease // Biochimie. 2002. 84: 273−278.
- Satyal S.H., Schmidt E., Kitagawa K., Sondheimer N., Lindquist S., Kramer J.M., Morimoto R.I. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans // PNAS. 2000. 97(11): 5750−5755.
- Lesort M., Chun W., Tucholski J., Johnson G.V. Does tissue transglutaminase play a role in Huntington’s disease. // Neurochem Int. 2002. 40(1): 37−52.
- Kim S., Nollen E.A., Kitagawa K., Bindokas V.P., Morimoto R.I. Polyglutamine protein aggregates are dynamic. // Nat Cell Biol. 2002. 4(10): 826 831.
- Suhr S.T., Senut M.C., Whitelegge J.P., Faull K.F., Cuizon D.B., Gage F.H. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. //J Cell Biol. 2001. 153(2): 283−294.
- Karpuj M.V., Becher M.W., Steinman L. Evidence for a role for transglutaminase in Huntington’s disease and the potential therapeutic implications //Neurochemistry International. 2002. 40: 31−36.
- Chai Y., Koppenhafer S.L., Bonini N.M., Paulson H.L. Analysis of the role of heat shock protein (Hsp) moleculat chaperones in polyglutamine disease.//J Neurosci. 1999. 19(23): 10 338−10 347.
- Violante V., Luongo A., Pepe I., Annunziata S., Gentile V. Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism of polyglutamine diseases. // Brain Res Bull. 2001. 56(3−4): 169−172.
- Balklava Z., Verderio E., Collighan R., Gross S., Adams J., Griffin M. Analysis of tissue transglutaminase function in the migration of swiss 3T3 fibroblasts. // J Biol Chem. 2002. 277(19): 16 567−16 575.
- Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S.,
- Pedotti R., Mitchell D., Steinman L. Prolonged survival and decreased abnormal91movements in transgenic model of Huntington’s disease, with administration of the transglutaminase inhibitor cystamine. // Nat Med. 2002. 8(2): 143−149.
- Jeon J.H., Lee H.J., Jang G.Y., Kim C.W., Shim D.M., Cho S.Y., Yeo E.J., Park S.C., Kim I.G. Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine. // Exp Mol Med. 2004. 36(6): 576−581.
- Berry M. Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders. // J. Psychiatry Neurosci., 2004. 29(5): 337−345.
- Burke J.R., Enghild J.J., Martin M.E., Jou Y.S., Myers R.M., Roses A.D., Vance J.M., Strittmatter W.J. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. // Nat. Med. 1996 2(3): 347−350.
- Mazzola J.L., Sirover M.A. Reduction of glyceraldehyde-3-phosphate dehydrogenase in Alzheimer’s disease and in Huntington’s disease fibroblasts // J. Neurochem. 2001. 76: 442−449.
- Senatorov V.V., Charles V., Reddy P.H., Tagle D.A., Chuang D.M. Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington’s disease. // Mol Cell Neurosci. 2003. 22(3): 285−297.
- Tatton W., Chalmers-Redman R., Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B // J. Neural Transm. 2003. 110: 509−515.
- Harjes P., Wanker E. The hunt for huntingtin function: interaction partners tell many different stories. // Trends Biochem Sci. 2003. 28(8): 425−433.
- Walker F.O. Huntington’s disease. // Lancet. 2007. 369(9557): 218 228.
- Pennuto M., Palazzolo I., Poletti A. Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. // Hum Mol Genet. 2009. 18(1): 40−47.
- Esposito C., Caputo I. Mammalian transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance. // FEBS J. 2005. 272(3): 615−631.
- Tisdale E.J., Kelly C., Artalejo C.R. Glyceraldehyde-3-phosphate dehydrogenase interacts with Rab2 and plays an essential role in endoplasmic reticulum to Golgi transport exclusive of its glycolytic activity. // J Biol Chem. 2004. 279(52): 54 046−54 052.
- Raje C.I., Kumar S., Harle A., Nanda J.S., Raje M. The macrophage cell surface glyceraldehyde-3-phosphate dehydrogenase is a novel transferrin receptor. // J Biol Chem. 2007. 282(5): 3252−3261.
- Hara M.R., Agrawal N., Kim S.F., Cascio M.B., Fujimuro M., Ozeki
- Y., Takahashi M., Cheah J.H., Tankou S.K., Hester L.D., Ferris C.D., Hayward
- S.D., Snyder S.H., Sawa A. S-nitrosylated GAPDH initiates apoptotic cell death by94nuclear translocation following Siahl binding. // Nat Cell Biol. 2005. 7(7): 665 674.
- Rathmell J.C., Kornbluth S. Filling a GAP (DH) in caspase-independent cell death. // Cell. 2007. 129(5): 861−863.
- Azam S., Jouvet N., Jilani A., Vongsamphanh R. Yang X., Yang S., Ramotar D. Human glyceraldehyde-3-phosphate dehydrogenase plays a direct role in reactivating oxidized forms of the DNA repair enzyme APE1. // J Biol Chem. 2008. 283(45): 30 632−30 641.
- Sen N., Hara M.R., Kornberg M.D., Cascio M.B., Bae B.I., Shahani N., Thomas B., Dawson T.M., Dawson V.L., Snyder S.H., Sawa A. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. // Nat Cell Biol. 2008. 10(7): 866−873.
- Hara M.R., Thomas B., Cascio M.B., Bae B., Hester L.D., Dawson V.L., Dawson T.M., Sawa A., Snyder S.H. Neuroprotection by pharmacologic blocade of the GAPDH death cascade. // PNAS. 2006. 103(10): 3887−3889.
- Tabakman R., Lecht S., Lazarovici P. Neuroprotection by monoamine oxidase B inhibitirs: a therapeutic strategy for Parkinson’s disease? // BioEssays, 2003. 26: 80−90.
- Magyar K., Szende B., Lengyel J., Tarczali J., Szatmary I. The neuroprotective and neuronal rescue effects of (-)-deprenyl. // J. Neural. Transm. 1998. 52: 109−123.
- Maruyama W., Takahashi T., Naoi M. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. // J. Neurochem. 1998. 70: 2510−2515.
- Paterson I.A., Barber A.J., Gelowitz D.L., Voll C. (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. // Neurosci. Biobehav. Rev. 1997. 21: 181−186.
- Tatton W., Chalmers-Redman R., Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehydes-3-phosphate dehydrogenase rather than monoamine oxidase B. // J. Neural. Transm. 2003. 110: 509−515.
- Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. // Lancet. 1996. 347(9013): 1425−1431.
- Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. //N. Engl. J. Med. 1994. 330(9): 585−591.
- Jimonet P., Audiau F., Barreau M., Blanchard J.C., Boireau A., Bour
- Y., Coleno M.A., Doble A., Doerflinger G., Huu C.D., Donat M.H., Duchesne
- J.M., Ganil P., Gueremy C., Honor E., Just B., Kerphirique R., Gontier S., Hubert97
- Ohtsuka K., Suzuki T. Roles of molecular chaperones in the nervous systems // Brain Research Bulletin. 2000. 53(2): 141−146.
- Bao Y.P., Sarkar S., Uyama E., Rubinsztein D.C. Congo red, doxycycline, and HSP70 overexpression reduce aggregate formation and cell death in cell models of oculopharyngeal muscular dystrophy. // J. Med. Genet. 2004. 41(1): 47−51.
- Muchowski P.J., Schaffar G., Sittler A., Wanker E.E., Hayer-Hartl M.K., Hartl F.U. Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. // Proc Natl Acad Sci USA. 2000. 97(14): 7841−7846.
- Chai Y., Koppenhafer S.L., Bonini N.M., Paulson H.L. Analysis of the role of heat shock protein (Hsp) moleculat chaperones in polyglutamine disease.//J Neurosci. 1999. 19(23): 10 338−10 347.
- Kim S., Nollen E.A., Kitagawa K., Bindokas V.P., Morimoto R.I. Polyglutamine protein aggregates are dynamic. // Nat Cell Biol. 2002. 4(10): 826 831.
- Grossmann M.E., Madden B.J., Gao F., Pang Y.P., Carpenter J.E., McCormick D., Young C.Y. Proteomics shows Hsp70 does not bind peptide sequences indiscriminately in vivo. // Exp Cell Res. 2004. 297(1): 108−117.
- Jindal S. Heat shock proteins: applications in health and disease // Biotech. 1996. 141: 17−20.
- Маргулис Б.А., Гужова И. В. Белки стресса в эукариотической клетке // Цитология. 2000, 42(4): С.323−338.
- Vargas-Roig L.M., Gago F.E., Tello О., Aznar J.C., Ciocca D.R. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. // Int. J. Cancer. 1998. 79(5): 468−475.
- Hartl F.U., Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein // Science. 2002. 295: 1852−1858.
- Nollen E.A., Morimoto R.I. Chaperoning signaling pathways: molecular chaperones as stress-sensing «heat shock» proteins // J. Cell Science. 2002. 115: 2809−2816.
- Martin J., Hartl F.U. Chaperone-assisted protein folding // Current opinion in structural biology. 1997. 7: P.41−52.99
- Reiner A., Albin R.L., Anderson K.D., D’Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. // Proc Natl Acad Sci USA. 1988. 85(15): 5733−5737.
- Landles C., Bates G.P. Huntingtin and the molecular pathogenesis of Huntington’s disease EMBO Rep. 2004. 5(10): 958−963.
- Bates G. Huntingtin aggregation and toxicity in Huntington’s disease. //Lancet. 2003. 361(9369): 1642−1644.
- Perutz M.F., Johnson T., Suzuki M., Finch J.T. Glutamine repeats as polar zippers: heir possible role in inherited neurodegenerative diseases. // Proc Natl Acad Sci USA. 1994. 91(12): 5355−5358.
- Caccamo D, Curro M, Ferlazzo N, Condello S, Ientile R. Monitoring of transglutaminase 2 under different oxidative stress conditions. // Amino Acids. 2012. 42(2−3): 1037−1043.
- Caccamo D., Curro M., Ientile R. Potential of transglutaminase 2 as a therapeutic target. // Expert Opin Ther Targets. 2010. 14(9): 989−1003.
- Calkins MJ, Townsend JA, Johnson DA, Johnson JA. Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription. //ExpNeurol. 2010. 224(1): 307−317.
- Bailey C.D., Johnson G.V. The protective effects of cystamine in the R6/2 Huntington’s disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. //Neurobiol Aging. 2006. 27(6): 871−879.
- Kumar A, Kneynsberg A, Tucholski J, Perry G, van Groen T, Detloff PJ, Lesort M. Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington’s disease. // Exp Neurol. 2012 237(1): 78−89.
- Lorand L., Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. // Nat Rev Mol Cell Biol. 2003. 4(2): 140−156.
- Martin A., Giuliano A., Collaro D., De Vivo G., Sedia C., Serretiello E., Gentile V. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases. // Amino Acids. 2013. 44(1): 111 118.
- Butterfield D.A., Hardas S.S., Lange M.L. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer’s disease: many pathways to neurodegeneration. // J Alzheimers Dis. 2010. 20(2): 369−393.
- Tristan C., Shahani N., Sedlak T.W., Sawa A. The diverse functions of GAPDH: views from different subcellular compartments. // Cell Signal. 2011. 23(2): 317−323.
- Arutyunov D.Y., Muronetz V.I. The activation of glycolysis performed by the non-phosphorylating glyceraldehyde-3- phosphatedehydrogenase in the model system. // Biochem Biophys Res Commun. 2003. 300(1): 149−154.
- Chuang D.M., Hough C., Senatorov V.V. Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. // Annu Rev Pharmacol Toxicol. 2005. 45: 269−290.
- Zheng L., Roeder R.G., Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a keycomponent. // Cell. 2003. 114(2): 255−266.
- Tarze A., Deniaud A., Le Bras M., Maillier E., Molle D., Larochette N., Zamzami N., Jan G., Kroemer G., Brenner C. GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. // Oncogene. 2007. 26(18): 2606−2620.
- Sergienko E.A., Kharitonenkov A.I., Bulargina T.V., Muronetz V.V., Nagradova N.K. D-glyceraldehyde-3-phosphate dehydrogenase purified from rabbit muscle contains phosphotyrosine. // FEBS Lett. 1992. 304(1): 21−23.
- Saunders P.A., Chen R.W., Chuang D.M. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis. // J Neurochem. 1999. 72(3): 925−932.
- Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR. p53 induces apoptosis by caspase activation through mitochondrial cytochrome с release. // J Biol Chem. 2000. 275(10): 7337−7342.
- Birkmayer W., Riederer P., Youdim M.B., Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of МАО-B, Deprenil. // J Neural Transm. 1975. 36(3−4): 303−326.
- Verdier Y, Foldi I., Sergeant N., Fulop L., Penke Z., Janaky Т., Szucs M., Penke B. Characterization of the interaction between Abeta 1−42 and glyceraldehyde phosphodehydrogenase. //J Pept Sei. 2008. 14(6): 755−762.
- Naletova I., Schmalhausen E., Kharitonov A., Katrukha A., Saso L., Caprioli A., Muronetz V. Non-native glyceraldehyde-3-phosphate dehydrogenase can be an intrinsic component of amyloid structures. // Biochim Biophys Acta. 2008. 1784(12): 2052−2058.
- Samii A., Nutt J.G., Ransom B.R. Parkinson’s disease. // Lancet. 2004. 363(9423): 1783−93.
- Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. // Cell. 1998. 95(1): 4153.
- Uchida K., Stadtman E.R. Covalent attachment of 4-hydroxynonenalto glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra104and intermolecular cross-linking reaction. // J Biol Chem. 1993. 268(9): 63 886 393.
- Botzen D., Grune T. Degradation of HNE-modified proteins—possible role of ubiquitin. // Redox Rep. 2007. 12(1): 63−67.
- Rubinsztein D.C., Carmichael J. Huntington’s disease: molecular basis of neurodegeneration. // Expert Rev Mol Med. 2003. 5(20): 1−21.
- Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. //Nature. 2004. 431(7010): 805−810.
- Cattaneo E., Zuccato C., Tartari M. Normal huntingtin function: an alternative approach to Huntington’s disease. // Nat Rev Neurosci. 2005. 6(12): 919−930.
- Ashizawa T., Wong L.J., Richards C.S., Caskey C.T., Jankovic J. CAG repeat size and clinical presentation in Huntington’s disease. // Neurology. 1994. 44(6): 1137−1143.
- Novak M.J., Tabrizi S.J. Huntington’s disease. // BMJ. 2010. 340: c3109.
- Bodai L., Pallos J., Thompson L.M., Marsh J.L. Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington’s disease. // Neurodegener Dis. 2012. 9(2): 104−106.
- Qin Z.H., Wang Y., Sapp E., Cuiffo В., Wanker E., Hayden M.R., Kegel K.B., Aronin N., DiFiglia M.J. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. // Neurosci. 2004. 24(1): 269−281.
- Еременко E.M., Антимонова О. И., Шекалова О. Г., Полоник С. Г., Маргулис Б. А., Гужова И. В. Новые соединения, повышающие экспрессию шаперона Hsp70, и их биологическая активность. // Цитология. 2010. 52: 235 241.
- Novoselova T.V., Margulis В.A., Novoselov S.S., Sapozhnikov A.M., van der Spuy J., Cheetham M.E., Guzhova I.V. Treatment with extracellular HSP70/HSC70 protein can reduce polyglutamine toxicity and aggregation. // J Neurochem. 2005. 94(3): 597−606.
- Margulis B., Kinev A., Guzhova I. Chaperones in neurodegenerative pathologies: Therapeutic prospects. // «Heat Shock Proteins in Biology and Medicine». 2006. Kerala, India: Research Signpost: 305−329.
- Sirover M.A. On the functional diversity of glyceraldehyde-3 -phosphate dehydrogenase: biochemical mechanisms and regulatory control. // Biochim Biophys Acta. 2011. 1810(8): 741−751.
- Jenkins J.L., Tanner J.J. High-resolution structure of human D-glyceraldehyde-3-phosphate dehydrogenase. // Acta Crystallogr D Biol Crystallogr. 2006. 62(P3): 290−301.
- Corbin I.R., Gong Y., Zhang M., Minuk G.Y. Proliferative and nutritional dependent regulation of glyceraldehyde-3-phosphate dehydrogenase expressionin the rat liver. // Cell Prolif. 2002. 35(3): 173−182.
- Raje C.I., Kumar S., Harle A., Nanda J.S., Raje M. J The macrophage cell surface glyceraldehyde-3-phosphate dehydrogenase is a novel transferrin receptor. //Biol Chem. 2007. 282(5): 3252−3261.
- Turner M.R., Parton M.J., Shaw C.E., Leigh P.N., Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King’s database 1990−2002. // J Neurol Neurosurg Psychiatry. 2003. 74(7): 995−997.
- Urushitani M., Kurisu J., Tsukita K., Takahashi R. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. // J Neurochem. 2002. 83(5): 1030−1042.
- Musaro A. State of the art and the dark side of amyotrophic lateral sclerosis. // World J Biol Chem. 2010. 1(5): 62−68.
- Imamoto N, Kose S. Heat-shock stress activates a novel nuclear import pathway mediated by Hikeshi. // Nucleus. 2012. 3(5): 422−428.
- Mayer M.P., Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. // Cell Mol Life Sci. 2005. 62(6): 670−684.
- Griffin M., Casadio R., Bergamini C.M. Transglutaminases: nature’sbiological glues. // Biochem J. 2002. 368(Pt 2): 377−396.109
- Vermes I., Steur E.N., Jirikowski G.F., Haanen C. Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson’s disease indicating apoptosis. // Mov Disord. 2004. 19(10): 1252−1254.
- Dudek N.L., Dai Y., Muma N.A. Neuroprotective effects of calmodulin peptide 76−12laa: disruption of calmodulin binding to mutant huntingtin. // Brain Pathol. 2010. 20(1): 176−189.
- Sabatelli M., Madia F., Conte A., Luigetti M., Zollino M., Mancuso I., Lo Monaco M., Lippi G., Tonali P. Natural history of young-adult amyotrophic lateral sclerosis. //Neurology. 2008. 71(12): 876−881.
- Ratovitski T., Chighladze E., Waldron E., Hirschhorn R.R., Ross C.A. Cysteine proteases bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of mutanthuntingtin. // J Biol Chem. 2011. 286(14): 12 578−12 589.
- Kim Y.J., Yi Y., Sapp E., Wang Y., Cuiffo B., Kegel K.B., Qin Z.H.,
- Shaw P.J. Molecular and cellular pathways of neurodegeneration in motor neurone disease. // J Neurol Neurosurg Psychiatry 2005. 76: 1046−1057.
- Ross C.A., Wood J.D., Schilling G., Peters M.F., Nucifora F.C., Cooper J.K., Sharp A.H., Margolis R.L., Borchelt D.R. Polyglutamine pathogenesis. // Philos Trans R Soc Lond B Biol Sci. 1999. 354(1386): 1005−1011.
- Davies S., Ramsden D.B. Huntington’s disease. // Mol Pathol. 2001. 54(6): 409−413.
- Wang J., Gines S., MacDonald M.E., Gusella J.F. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. // BMC Neurosci. 2005. 6:1.
- Noguchi K., Ishikawa K., Yokoyama K.i., Ohtsuka T., Nio N., Suzuki E. Crystal structure of red sea bream transglutaminase. // J Biol Chem. 2001. 276(15): 12 055−12 059.
- Lesort M, Attanavanich K, Zhang J, Johnson GV. Distinct nuclear localization and activity of tissue transglutaminase. // J Biol Chem. 1998. 273(20): 11 991−11 994.
- Schulte J., Littleton J.T. The biological function of the Huntingtin protein and its relevance to Huntington’s Disease pathology. // Curr Trends Neurol. 2011. 5: 65−78.
- Bush A.I. Is ALS caused by an altered oxidative activity of mutant superoxide dismutase? // Nat Neurosci. 2002. 5(10): 919.
- Seetharaman S.V., Prudencio M., Karch C., Holloway S.P., Borchelt D.R., Hart P.J. Immature copper-zinc superoxide dismutase and familial amyotrophic lateral sclerosis. // Exp Biol Med. 2009. 234(10): 1140−1154.
- Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. // Antioxid Redox Signal. 2011. 15(6): 1583−1606.
- Deng H.X., Hentati A., Tainer J.A., Iqbal Z., Cayabyab A., Hung W.Y., Getzoff E.D., Hu P., Herzfeldt B., Roos R.P., et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. // Science. 1993. 261(5124): 1047−1051.
- Milani P., Gagliardi S., Cova E., Cereda C. SOD1 Transcriptional and Posttranscriptional Regulation and Its Potential Implications in ALS. // Neurol Res Int. 2011.2011: 458 427.
- Arawaka S., Machiya Y., Kato T. Heat shock proteins as suppressors of accumulation of toxic prefibrillar intermediates and misfolded proteins in neurodegenerative diseases. // Curr Pharm Biotechnol. 2010. 11(2): 158−166.
- Hyun D.H., Lee M., Halliwell B., Jenner P. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. // J Neurochem. 2003. 86(2): 363−373.
- Wadhwa R., Taira K., Kaul S.C. An Hsp70 family chaperone, ortalin/mthsp70/PBP74/Grp75: what, when, and where? // Cell Stress Chaperones. 2002. 7(3): 309−316.
- Labbadia J., Novoselov S.S., Bett J.S., Weiss A., Paganetti P., Bates G.P., Cheetham M.E. Suppression of protein aggregation by chaperone modification of high molecular weight complexes. // Brain. 2012. 135(Pt 4): 11 801 196.
- Yun M., Park C.G., Kim J.Y., Park H.W. Structural analysis of glyceraldehyde 3-phosphate dehydrogenase from Escherichia coli: direct evidence of substrate binding and cofactor-induced conformational changes. //
- Biochemistry. 2000. 39(35): 10 702−10 710.113
- Huang J., Hao L., Xiong N., Cao X., Liang Z., Sun S., Wang T. Involvement of glyceraldehyde-3-phosphate dehydrogenase in rotenone-induced cell apoptosis: relevance to protein misfolding and aggregation. // Brain Res. 2009. 1279: 1−8.
- Chun W., Lesort M., Tucholski J., Faber P.W., MacDonald M.E., Ross C.A., Johnson G.V. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells. // Neurobiol Dis. 2001. 8(3): 391−404.